Genome-wide investigation of intragenic DNA methylation identifies ZMIZ1 gene as a prognostic marker in glioblastoma and multiple cancer types INTERNATIONAL JOURNAL OF CANCER Mathios, D., Hwang, T., Xia, Y., Phallen, J., Rui, Y., See, A. P., Maxwell, R., Belcaid, Z., Casaos, J., Burger, P. C., McDonald, K. L., Gallia, G. L., Cope, L., Kai, M., Brem, H., Pardoll, D. M., Ha, P., Green, J. J., Velculescu, V. E., Bettegowda, C., Park, C., Lim, M. 2019; 145 (12): 3425–35


DNA methylation has long been recognized as a tumor-promoting factor when aberrantly regulated in the promoter region of genes. However, the effect of intragenic DNA methylation remains poorly understood on the clinical aspects of cancer. Here, we first evaluated the significance of intragenic DNA methylation for survival outcomes of cancer patients in a genome-wide manner. Glioblastoma patients with hypermethylated intragenic regions exhibited better survival than hypomethylated patients. Enrichment analyses of intragenic DNA methylation profiles with epigenetic signatures prioritized the intragenic DNA methylation of ZMIZ1 as a possible glioblastoma prognostic marker that is independent of MGMT methylation in IDH1 wild-type patients. This intragenic region harbored molecular signatures of alternative transcription across many cell types. Furthermore, we found that the intragenic region of ZMIZ1 can serve as a molecular marker in multiple cancers including astrocytomas, bladder cancer and renal cell carcinoma according to DNA methylation status. Finally, in vitro and in vivo experiments uncovered the role of ZMIZ1 as a driver of tumor cell migration. Altogether, our results identify ZMIZ1 as a prognostic marker in cancer and highlight the clinical significance of intragenic methylation in cancer.

View details for DOI 10.1002/ijc.32587

View details for Web of Science ID 000491231500023

View details for PubMedID 31373686